GLP-1 starter doses deliver 5.5% or less weight loss, study finds
AI Summary- Researchers compared low-dose semaglutide and tirzepatide for weight loss and adverse events.
- One-year average weight loss reached 5.5% with tirzepatide and 2.2% with semaglutide.
- Participants remained on approved starter doses for at least six months, the study said.